REBECCA SCARBROUGH: Open Payments
NPI 1518443134 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$673 in 31 payments from 11 companies in 2025. Trend: 2023 $618 · 2024 $372 · 2025 $673
Food & beverage: $673
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $177 |
| Abbott Laboratories | 9 | $169 |
| AstraZeneca Pharmaceuticals LP | 2 | $85 |
| Tandem Diabetes Care, Inc. | 2 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $16 |
Products named: FREESTYLE LIBRE, AIRSUPRA, Wegovy, Ozempic, t:slim X2 Insulin Pump with Control-IQ, Kerendia, JARDIANCE, TRELEGY ELLIPTA.
Industry payments across MS — which companies pay providers there.
